Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Topics Community

Article

Complement activation profiles in patients with immune checkpoint inhibitor-associated neuromuscular immune-related adverse events

12 Jun 2025

Abstract excerpt

BACKGROUND: Immune-related neuropathy (irNeuropathy) and myositis (irMyositis) are the most common neurologic adverse events (irAE-n) associated with immune checkpoint inhibitors. Although case reports suggest benefits of complement inhibitors, the role of complement activation in irAE-n is understudied. METHODS: In a retrospective multicenter study, we enrolled patients with irNeuropathy or irMyositis, cancer...

Source

Identifiers

PMID: 40506552
DOI: 10.1007/s00415-025-13181-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Complement activation profiles in patients with immune checkpoint inhibitor-associated neuromuscular immune-related adverse eventsPMID 40506552Read ↗

Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside.Semantic proximity Read ↗

Molecular pathways and cellular subsets associated with adverse clinical outcomes in overlapping immune-related myocarditis and myositisSemantic proximity Read ↗

Complement and MHC patterns can provide the diagnostic framework for inflammatory neuromuscular diseasesSemantic proximity Read ↗

Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathiesSemantic proximity Read ↗

Contribution of Complement, Microangiopathy and Inflammation in Idiopathic Inflammatory MyopathiesSemantic proximity Read ↗

A retrospective study for clinical characteristics of 293 patients with dermatomyositis.Semantic proximity Read ↗

Dermatomyositis predominates among checkpoint inhibitor-associated inflammatory myositis phenotypes: a pharmacovigilance disproportionality analysis identifies a class-wide signal.Semantic proximity Read ↗

Bridging clinical phenotypes with molecular mechanisms in autoimmune irAEs: An Etiopathogenic framework.Semantic proximity Read ↗

Deep Pathological Phenotyping of Dermatomyositis with Different AutoantibodiesSemantic proximity Read ↗

Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor-induced myositisSemantic proximity Read ↗

Prognostic and immune-related value of complement C1Q (C1QA, C1QB, and C1QC) in skin cutaneous melanomaSemantic proximity Read ↗

Complement Therapeutics in Autoimmune DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.